reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Talis Biomedical Corp

Not currently scored

This filer is no longer a domestic reporting company, so the score does not apply to it now. Its history is below.

$8.2Bstalepublic float
2024-09-20delisted or deregistered

Score over time

012202220232024202520262022-01-01 · score 12021-11-16 filed late (10-Q)2022-04-01 · score 12021-11-16 filed late (10-Q)2022-07-01 · score 12021-11-16 filed late (10-Q)2022-10-01 · score 12021-11-16 filed late (10-Q)2024-10-01 · score 12024-08-14 filed late (10-Q) · accounts not ready2025-01-01 · score 12024-08-14 filed late (10-Q) · accounts not ready2025-04-01 · score 12024-08-14 filed late (10-Q) · accounts not ready2025-07-01 · score 12024-08-14 filed late (10-Q) · accounts not ready

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Talis Biomedical Corporation (the “Company”) expects a delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “ Form 10-Q ”), within the prescribed time period without unreasonable effort or expense, because the Company requires additional time for compilation and review to ensure adequate disclosure of certain information required to be included in the Form 10-Q. The Company expects to file its Form 10-Q on or before the fifth calendar day extension provided by Rule 12b-25

NT 10-Q, filed 2024-08-14 · accounts not ready

What it filed

2024-08-14filed late (10-Q)accounts not ready SEC →

Talis Biomedical Corporation (the “Company”) expects a delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “ Form 10-Q ”), within the prescribed time period without unreasonable effort or expense, because the Company requires additional time for compilation and review to ensure adequate disclosure of certain information required to be included in the Form 10-Q. The Company expects to file its Form 10-Q on or before the fifth calendar day extension provided by Rule 12b-25

2021-11-16filed late (10-Q) SEC →

Talis Biomedical Corporation (the “Company”) was unable to file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Quarterly Report”) prior to the filing deadline of 5:30 p.m. Eastern Time on November 15, 2021. Despite working diligently in an effort to timely file the Quarterly Report, as a result of technical difficulties, the Quarterly Report was filed at approximately 5:35 p.m. Eastern Time on November 15, 2021, and therefore the Quarterly Report is deemed to be filed on November 16, 2021, which is past the filing deadline for the Quarterly Report. The Company is filing this Form 12b-25 to report the late filing of the Quarterly Report

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com